Composition for diagnosing follicular thyroid carcinoma using expression level of aminoacyl-tRNA synthetase-related protein and method for detecting diagnostic marker

Patent metadata

Field	Value
Publication number	US-10677806-B2
Application number	US-201816233695-A
Country	US
Kind code	B2
Filing date	Dec 27, 2018
Priority date	Jul 1, 2016
Publication date	Jun 9, 2020
Grant date	Jun 9, 2020

Abstract

A method for diagnosing follicular thyroid carcinoma is described. The method measures protein expression levels of an aminoacyl-tRNA synthetase (ARS) or an aminoacyl-tRNA synthetase complex-interacting multifunctional protein (AIMP) in a sample, such as a thyroid tissue sample, from a subject suspected of having follicular thyroid carcinoma. The protein expression levels of ARS or AIMP are compared to the measured protein expression levels in a control.

First claim

What is claimed is:

1. A method for treating a follicular thyroid carcinoma, the method comprising the steps of:
(a) obtaining a thyroid tissue sample from a human subject suspected of having follicular thyroid carcinoma;
(b) measuring the protein expression level of an aminoacyl-tRNA synthetase (ARS) or an aminoacyl-tRNA synthetase complex-interacting multifunctional protein (AIMP) in the sample;
(c) comparing the measured protein expression level of the subject with that of a control;
(d) diagnosing the subject with a follicular thyroid carcinoma when the protein expression level of the subject has a change in comparison with that of the control; and
(e) treating the diagnosed subject by conducting at least one of a chemotherapy, a surgery; and a radiation therapy.

2. The method of claim 1 , herein the control is a patient identified as having thyroid follicular adenoma.

3. The method of claim 1 , wherein the change in the protein expression level is an increase in the expression level of at least one protein selected from the group consisting of Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 (AIMP1), Isoleucyl-tRNA synthetase mitochondrial (IARS mitochondrial), seryl-tRNA synthetase mitochondrial (SARS mitochondria), lysyl-tRNA synthetase (KARS); valyl-tRNA synthetase (VARS), and phenylalanyl-tRNA synthetase alpha subunit (FARSA).

4. The method of claim 1 , wherein the change in the protein expression level is a decrease in the protein expression level of at least one protein selected from the group consisting of alanyl-tRNA synthetase (AARS), aspartyl-tRNA synthetase (DARS), bifunctional glutamyl-prolyl-tRNA synthetase (EPRS), tryptophanyl-tRNA synthetase (WARS), glycyl-tRNA synthetase (GARS), isoleucyl-tRNA synthetase cytoplasmic (IARS cytoplasmic), tyrosyl-tRNA synthetase (YARS), asparagyl-tRNA synthetase (NARS), glutaminyl-tRNA synthetase (OARS), arginyl-tRNA synthetase (RARS), seryl-tRNA synthetase cytoplasmic (SARS cytoplasmic) and threonyl-tRNA synthetase (TARS).

5. The method of claim 1 , wherein the measurement of the protein expression level is performed by a method selected from the group consisting of western blotting, dot blotting, enzyme-linked immunosorbant assay (ELISA), radio immune assay (RIA), radial immunodiffusion assay, Ouchterlony immunodiffusion, rocket immunoelectrophoresis, immunohistochemistry, immunoprecipitation, complement fixation assay, Flow Cytometry (FRCS), protein chip and mass spectrometry.

6. The method of claim 1 , wherein the aminoacyl-tRNA synthetase (ARS) is at least one selected from the group consisting of Isoleucyl-tRNA synthetase mitochondrial (IARS mitochondrial, GenBank GI No. 94730583), seryl-tRNA synthetase mitochondria (SARS mitochondria, GenBank GI No. 23822219), lysyl-tRNA synthetase (KARS, GenBank GI No. 20178333), valyl-tRNA synthetase (VARS, GenBank GI No. 1194845281), phenylalanyl-tRNA synthetase alpha subunit (FARSA, GenBank GI No. 12643946), alanyl-tRNA synthetase (AARS, GenBank GI No. 115502460), aspartyl-tRNA synthetase (GARS, GenBank GI No. 20178330), bifunctional glutamyl-prolyl-tRNA synthetase (EPRS, GenBank GI No. 288558855), tryptophanyl-tRNA synthetase (WARS, GenBank GI No. 135191), glycyl-tRNA synthetase (GARS, GenBank GI No. 313104283), isoleucyl-tRNA synthetase cytoplasmic (IARS cytoplasmic, GenBank GI No. 239938717), tyrosyl-tRNA synthetase (YAKS, GenBank GI No. 13638438), asparagyl-tRNA synthetase (NARS, GenBank GI No. 3915059), glutaminyl-tRNA synthetase (OARS, GenBank GI No. 1351170), arginyl-tRNA synthetase (BARS, GenBank GI No. 20178331), seryl-tRNA synthetase cytoplasmic (SARS cytoplasmic, GenBank GI No. 19860217) and threonyl-tRNA synthetase (TARS, GenBank GI No. 60267755).

7. The method of claim 1 , wherein the aminoacyl-tRNA synthetase complex-interacting multifunctional protein (AIMP) is an aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1, GenBank GI No. 215490009).

8. The method of claim 1 , wherein the step of measuring is conducted with a composition comprising an agent for measuring the expression level of an aminoacyl-tRNA synthetase (ARS) or an aminoacyl-tRNA synthetase complex-interacting multifunctional protein (AIMP).

9. The method of claim 8 , wherein the aminoacyl-tRNA synthetase (ARS) is at least one selected from the group consisting of Isoleucyl-tRNA synthetase mitochondrial (IARS mitochondrial), seryl-tRNA synthetase mitochondria (SARS mitochondria), lysyl-tRNA synthetase (KARS), valyl-tRNA synthetase (VARS), phenylalanyl-tRNA synthetase alpha subunit (FARSA), alanyl-tRNA synthetase (AARS), aspartyl-tRNA synthetase (DARS), bifunctional glutamyl-prolyl-tRNA synthetase (EPRS), tryptophanyl-tRNA synthetase (WARS), glycyl-tRNA synthetase (GARS), isoleucyl-tRNA synthetase cytoplasmic (IARS cytoplasmic), tyrosyl-tRNA synthetase (YARS), asparagyl-tRNA synthetase (MARS), glutaminyl-tRNA synthetase (OARS), arginyl-tRNA synthetase (BARS), seryl-tRNA synthetase cytoplasmic (SARS cytoplasmic) and threonyl-tRNA synthetase (TARS).

10. The method of claim 8 , wherein the aminoacyl-tRNA synthetase complex-interacting multifunctional protein (AIMP) is an aminoacyl-tRNA synthetase complex-interacting multifunctional protein 1 (AIMP1).

11. The method of claim 1 , wherein the follicular thyroid carcinoma is differentially diagnosed from a follicular adenoma.

12. The method of claim 8 , wherein the agent is a peptide, antibody, or aptamer comprising a binding domain specific for the ARS or AIMP protein.

13. The method of claim 8 , wherein the composition comprising the agent is contained in a kit for diagnosing a follicular thyroid carcinoma.

Assignees

• Medicinal Bioconvergence Res Ct
• Asan Found
• Univ Ulsan Found Ind Coop

Inventors

• Kim Sunghoon
• Yang Won Suk
• Kim Kyunggon
• Kim Won Gu

Classifications

• G01N33/57407

  Physics · mapped topic

• G01N33/573

  for enzymes or isoenzymes · CPC title

• G01N33/574

  Physics · mapped topic

• G01N33/78 Primary

  Thyroid gland hormones {, e.g. T3, T4, TBH, TBG or their receptors} · CPC title

• G01N33/57557 Primary

  of other specific parts of the body, e.g. brain · CPC title